Prostate, bladder and kidney cancer

Goals

• Finding early diagnostic indicators that can accurately identify patients with localized tumors who benefit from (minimally invasive) treatment while avoiding unnecessary biopsies and treatment;
• Developing and evaluating new treatment and diagnostic modalities with better efficacy and less mutilating effects;
• Finding pre- and on-treatment biomarkers that can identify or early discriminate patients  who are expected to respond to specific therapies;
• Identifying host–related risk factors as leads for primary and tertiary prevention;
• Optimize the risk-benefit ratio of available anticancer drugs through early identify.